Study Overview:

This is a first-in-human study to evaluate the safety, tolerability, and pharmacodynamics of a single IV infusion of NBIB-223 in participants with Friedreich’s Ataxia.

There are 3 participant groups/arms planned:

  • Part A: Dose escalation in adults
  • Part B: Dose expansion in pediatrics
  • Part C: Dose expansion in adult and/or pediatric participants with FA-related cardiomyopathy

Anyone considering participating in a clinical trial should discuss the matter with their physician. FARA does not endorse or recommend any particular studies. 

Study Details:

Key Inclusion Criteria:

  • Clinical and genetic diagnosis of Friedreich’s Ataxia.
  • Diagnosed before age 16.
  • GAA repeat expansion in both alleles.
  • Resides in the United States.
  • mFARS overall score ≥15 and <80, and an Upright Stability (mFARS-E) gait score of ≥1.
  • Omaveloxolone use:
    • If currently taking omaveloxolone, must have started at least 1 year ago and have been on a stable dose for at least 12 weeks with no anticipated dose adjustments during the 48-week period following NBIB-223 infusion.
    • If not currently taking omaveloxolone, must agree not to start during the 48-week period following NBIB-223 infusion.

Key Exclusion Criteria:

  • Pregnant, plan to become pregnant during the first 12 months of the study, or lactating.
  • Previous exposure to adeno-associated virus (AAV)-9 as determined by the presence of anti-AAV9 antibodies.
  • Contraindication to cerebrospinal fluid collection via lumbar puncture, magnetic resonance imaging with contrast, or endomyocardial biopsy.
  • Clinically significant cardiac valve disease, obstructive cardiac disease, or arrhythmias.
  • Uncontrolled diabetes (hemoglobin [Hb] A1c >8.0%).
  • Planned surgery for scoliosis, foot deformity, or other indications during the first 18 months.
  • Previously treated with cellular or gene therapy.
  • Participated in any other interventional clinical study within 30 days.

Additional inclusion/exclusion criteria may apply, per protocol.

Study Contact

Name: Neurocrine Medical Information Call Center

Phone Number: 1-877-641-3461

Email: medinfo@neurocrine.com

Participating Study Locations

Institution NameLocationStudy Coordinator and Contact Information

University of Florida

Gainesville, Florida, United States, 32608

Not Yet Recruiting 

PI: Sub Subramony
Study Contact: Melissa Pinard — mpinard@peds.ufl.edu

University of South Florida

Tampa, Florida, United States, 33612

Not Yet Recruiting 

PI: Theresa Zesiewicz
Study Contacts:

University of Iowa

Iowa City, Iowa, United States, 52242

Not Yet Recruiting 

PI: Dimah Saade
Study Contact: Ciara Gibbs — ciara-gibbs@uiowa.edu

CHOP/UPenn

Philadelphia, Pennsylvania, United States, 19406

Not Yet Recruiting 

PI: David Lynch
Study Contacts:

Understanding Genetic Therapies for Friedreich's Ataxia

Genetic therapies are treatments that target FA at the DNA level. This is a rapidly growing field. As FA genetic therapy programs move toward clinical trials, understanding how these therapies work can help you make informed decisions about participation.

Learn more about genetic therapies on our website page or watch FARA’s educational video here.

Screenshot 2026 08 12 at 2.56.55 PM scaled

Explore the FA Drug Development Pipeline

FARA believes treating FA will take multiple therapies working together to slow, stop, reverse, and cure FA. Learn more about NBIB-223 and explore the other approaches in the FA Drug Development pipeline.